I’m not so sure. When pharma companies are flush with cash they tend to get more experimental. Lilly’s gene editing group is one of the few that’s doing well (l

I’m not so sure. When pharma companies are flush with cash they tend to get more experimental. Lilly’s gene editing group is one of the few that’s doing well (last I heard anyway) and they recently acquired Verve. I can’t imagine that would happen without GLP-1 profits bankrolling everything. Rare disease is effectively charity and the money has to come from somewhere.